U.S. President Donald Trump's recent executive order on drug pricing poses a risk to Roche's planned $50 billion investment in the U.S. Roche stated that if the order, which aims to align brand-name drug prices with those in other wealthy nations, is implemented, it could jeopardize their ability to make significant investments announced earlier. While Roche does not foresee immediate business impacts, the company plans to engage with the Trump administration regarding this policy. Other pharmaceutical giants like Novartis remain committed to their investment strategies despite ongoing discussions about pricing reforms.
Roche's ability to fund significant investments in the U.S. will be in question if Trump's executive order goes into effect.
We are working both in the U.S. and Europe to advocate necessary changes, including reducing the role of pharmacy benefit managers.
Collection
[
|
...
]